Recommendation for Topical Treatment of Extensive Actinic Keratoses
For an 89-year-old man with extensive actinic keratoses, I recommend using 5-fluorouracil 5% cream over imiquimod 5% cream, based on superior long-term sustained clearance and the patient's age considerations.
Rationale Based on Evidence
Efficacy Comparison
The British Association of Dermatologists 2017 guidelines provide the most comprehensive comparison data 1. In a critical three-armed RCT directly comparing these agents, imiquimod demonstrated markedly superior sustained clearance at 12 months: 76% of patients maintained clearance with imiquimod versus only 33% with 5-FU 5% 1. This represents more than double the long-term efficacy.
While a Cochrane meta-analysis ranked 5-FU at the top for initial clearance 1, and one head-to-head study showed 5-FU achieved 84% complete clearance versus imiquimod's 24% at week 24 2, these short-term results are contradicted by the sustained clearance data. The most recent real-world cohort study (2018) found that 5-FU reduced short-term risk of subsequent AKs but showed no statistically significant long-term benefit compared to imiquimod (cumulative risk difference -1.43%, 95% CI -3.43% to 0.05%) 3.
Critical Age-Related Considerations for This Patient
At 89 years old, several factors favor imiquimod:
Treatment burden: 5-FU requires twice-daily application for 2-4 weeks 1, while imiquimod is applied 3 times weekly for 4-8 weeks 1. The less frequent dosing may improve adherence in an elderly patient.
Tolerability profile: Both agents cause local skin reactions, but the guidelines note that imiquimod's side-effects are "generally well tolerated" 1. In elderly patients with potentially fragile skin, the ability to modulate treatment frequency is valuable.
Sustained benefit: Given limited life expectancy considerations, the superior 12-month sustained clearance with imiquimod (76% vs 33%) 1 is clinically more relevant than initial clearance rates.
However, 5-FU Remains a Valid Alternative If:
The 2021 AAD guidelines give both agents strong recommendations (Grade A) 4. Consider 5-FU if:
- Hyperkeratotic lesions are present: The 0.5% 5-FU in 10% salicylic acid formulation specifically addresses more keratotic AKs 1
- Rapid initial clearance is prioritized: 5-FU demonstrates faster visible response 2
- Cost is a primary concern: 5-FU is described as "widely used, flexible and low-cost" 1
Practical Application Algorithm
For non-hyperkeratotic, non-hypertrophic AKs (typical presentation):
- Start with imiquimod 5% cream applied 3 nights per week for 4 weeks
- Wash off after 8 hours
- Repeat for additional 4 weeks if needed
- Expect 50-84% complete clearance with 76% maintaining clearance at 12 months 1
For hyperkeratotic lesions:
- Consider 5-FU 0.5% in 10% salicylic acid formulation
- Apply daily for 6-12 weeks or until clearance
- Achieved 55.4% complete clearance in trials 1
Common Pitfalls to Avoid
Inadequate patient counseling: Both treatments cause significant local reactions (erythema, crusting, soreness). Approximately 50% of patients discontinue at 6 weeks due to lesion disappearance 1. Counsel that this is expected and treatment should continue as prescribed.
Excessive treatment area: Limit 5-FU to maximum 500 cm² due to toxicity concerns 1. For extensive disease, treat in stages.
Poor healing sites: Exercise extreme caution with 5-FU on lower legs in elderly patients 1. Imiquimod may be safer in these locations.
Failure to manage side effects: Provide strategies including treatment breaks, frequency reduction, emollients, and weak topical steroids for excessive reactions 1.
Ignoring field therapy concept: With "extensive" actinic keratoses, both visible and subclinical lesions require treatment. Field-directed therapy addresses this better than lesion-directed approaches.
Monitoring and Follow-up
Real-world data shows patients still required an average of 3.3 fewer cryosurgery spot treatments after 5-FU and 2.0 fewer after imiquimod 5, indicating that additional procedural treatments may still be necessary for residual lesions.